Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (NCT07727967) titled 'Oral Lactobacillus Crispatus Lc-G22 as Adjunctive Therapy for Vulvovaginal Candidiasis' on July 21.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Single (Participant).

Primary Sponsor: BioGrowing Co., Ltd

Condition: Vulvovaginal Candidiasis

Intervention: Dietary Supplement: Lactobacillus crispatus Lc-G22

Recruitment Status: Not recruiting

Phase: N/A

Date of First Enrollment: July 1, 2022

Target Sample Size: 100

Countries of Recruitment: China

To know more, visit https://clinicaltrials.gov/study/NCT07727967...